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Introduction: Pediatric patients with cardiac congenital diseases require heart valve
implants that can grow with their natural somatic increase in size. Current artificial valves
perform poorly in children and cannot grow; thus, living-tissue-engineered valves capable
of sustaining matrix homeostasis could overcome the current drawbacks of artificial
prostheses and minimize the need for repeat surgeries.
Materials and Methods: To prepare living-tissue-engineered valves, we produced
completely acellular ovine pulmonary valves by perfusion. We then collected autologous
adipose tissue, isolated stem cells, and differentiated them into fibroblasts and separately
into endothelial cells. We seeded the fibroblasts in the cusp interstitium and onto the
root adventitia and the endothelial cells inside the lumen, conditioned the living valves
in dedicated pulmonary heart valve bioreactors, and pursued orthotopic implantation
of autologous cell-seeded valves with 6 months follow-up. Unseeded valves served
as controls.
Results: Perfusion decellularization yielded acellular pulmonary valves that were stable,
no degradable in vivo, cell friendly and biocompatible, had excellent hemodynamics,
were not immunogenic or inflammatory, non thrombogenic, did not calcify in juvenile
sheep, and served as substrates for cell repopulation. Autologous adipose-derived stem
cells were easy to isolate and differentiate into fibroblasts and endothelial-like cells.
Cell-seeded valves exhibited preserved viability after progressive bioreactor conditioning
and functioned well in vivo for 6 months. At explantation, the implants and anastomoses
were intact, and the valve root was well integrated into host tissues; valve leaflets were
unchanged in size, non fibrotic, supple, and functional. Numerous cells positive for
a-smooth muscle cell actin were found mostly in the sinus, base, and the fibrosa of the
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leaflets, andmost surfaces were covered by endothelial cells, indicating a strong potential
for repopulation of the scaffold.
Conclusions: Tissue-engineered living valves can be generated in vitro using the
approach described here. The technology is not trivial and can provide numerous
challenges and opportunities, which are discussed in detail in this paper. Overall, we
concluded that cell seeding did not negatively affect tissue-engineered heart valve (TEHV)
performance as they exhibited as good hemodynamic performance as acellular valves
in this model. Further understanding of cell fate after implantation and the timeline of
repopulation of acellular scaffolds will help us evaluate the translational potential of
this technology.
Keywords: acellular scaffolds, autologous cells, bioreactor conditioning, orthotopic implantation, cell seeding
INTRODUCTION
The most frequent pathology in the pediatric population is
represented by congenital involvement of the right ventricular
outflow tract, accounting for 20% of the total number of
cardiac congenital malformations (1). Present alone or
associated with other tissues, pulmonary valve stenosis is
ranked third in the list of most frequent congenital cardiac
conditions (2). For pulmonary valve replacement in this age
category group, biological prostheses are preferred, those
including the classical glutaraldehyde fixed, cryopreserved
homograft bioprostheses, decellularized homografts, or
mechanical valves (3). Artificial mechanical valves have the
downside of requiring lifelong anticoagulation, whereas the
biological valves are characterized by a limited lifespan and
functionality, especially in children (4). Heart valve replacement
in pediatric patients is a challenging endeavor; in addition
to the technical surgical complexity, current valve prosthesis
models cannot grow with the somatic growth of the patient
and thus require multiple open-heart reinterventions until
adulthood (5).
The field of regenerative medicine and tissue engineering
strives to develop the next generation of heart valve substitutes,
i.e., living-tissue-engineered heart valves (living TEHVs), which
could overcome the current available drawbacks of artificial
prostheses. Having their own metabolism, TEHVs are expected
to have the capacity to grow and develop simultaneously with
the body, with no need for anticoagulation and minimal long-
term degeneration (6). Essentially composed of scaffolds and
cells (7), manufacturing this new type of heart valve substitute
represents a research task involving multidisciplinary teams and
several challenges. Studies of synthetic (polymeric) scaffolds
seeded with endothelial cells and myofibroblasts (8) showed that
the presence of repopulating cells was associated with valvular
insufficiency secondary to cusps remodeling and retraction.
Scaffolds seededwith autologous stem cells (9), or just endothelial
cells (10), also revealed multiple drawbacks, a major one being
the fibrosis and contraction of the cusps, induced by the seeded
cells (9, 11).
Recently, a switch in the traditional paradigm has occurred,
where scientists implanted degradable or no degradable scaffolds
and used the host body as a living bioreactor, repopulating
the scaffold with autologous cells after implantation. In animal
models, these scaffolds performed well for 4–6 months,
fulfilling their mechanical function. Currently, ongoing clinical
trials investigating the behavior of decellularized pulmonary
valves implanted in humans are ongoing (12), as well as
heart valve replacements with other acellular scaffolds (13).
These scaffolds are developed by removal of all antigenic
cells, using detergents. They are based on an extracellular
matrix composed of collagen and elastin fibers, which are
not entirely intact (collagen peptides are released); therefore,
after implantation, they could be a target for proteases from
infiltrating cells, especially under adverse mechanical and
biochemical conditions. In order to create a living heart
valve, able to not only accomplish the critical mechanical
function but also maintain the matrix homeostasis and respond
to stimuli in physiological and/or pathological environments,
we developed a pulmonary valve based on a decellularized
scaffold seeded with fibroblasts and endothelial cells (ECs)
derived from autologous adipose tissue-derived stem cells.
Our hypothesis is that a living-TEHV with a controlled
composition at cellular and extracellular level will accomplish
its mechanical function similarly to the native valve. Our TEHV
technology includes three elements: (1) decellularized valve
scaffolds as themost suitable biological, structural, and functional
component; (2) autologous cells seeded in the appropriate
tissue layers for matrix homeostasis; (3) dynamic conditioning
in bioreactors before implantation for cell adaptation to
physiologic stress.
To test our hypothesis, we proposed the preclinical
validation of a scenario with significant translational potential
(Figure 1). Briefly, this involves in vitro repopulation of
decellularized pulmonary valves by seeding with autologous
fibroblasts (FBs) and ECs derived from adipose tissue-
derived stem cells, preconditioning of the living valves
in dedicated pulmonary heart valve bioreactors, and
orthotopic implantation in sheep with 6 months follow-
up. Each step of this scenario is described in detail,
documented by results, and complemented by discussion
of the challenges encountered and opportunities offered by
the study.
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FIGURE 1 | Project overview. Flowchart depicting the main translational scenario steps that were tested in this study. After animal selection (1), adipose tissue was
collected under aseptic conditions (2), the tissue transported to the lab in culture medium (3), and stem cells isolated and propagated (4). For differentiation, cells
were split in two batches and separately differentiated into ECs (5) and FBs (6). Then FBs and ECs were used to seed the acellular valve scaffolds (7) by injection and
rotation (8). Seeded valves were subjected to BR conditioning in sterile media (9) and transported to the operating theater where they were prepared (10) and then
implanted orthotopically as autologous implants (11) in the same animal from which the stem cells had been collected.
MATERIALS AND METHODS
Scaffolds
Ovine hearts were collected immediately after euthanasia at
a local abattoir. Animals were represented by mature sheep
(male and female, aged 1.5–2.0 years, weighing 50–60 kg). The
harvesting technique consisted in maintaining the pericardial
sack, ascending aorta, and the pulmonary trunk intact. Following
harvesting, hearts were transported on ice to the laboratory
for dissection.
The ovine pulmonary valves (n = 15) were dissected and
extracted with sterile basic surgical tools, preserving 3–4 cm of
the circumferentially oriented myocardium at the valve base.
Distally, the arterial tissue was sectioned at the level of the
pulmonary trunk bifurcation (about 5–6 cm height from the
cusps commissure). After rinsing, valve roots were placed in the
MechAnnulusTM mounting rings by clamping the myocardium
between interlocking metal rings and set in the decellularization
system (PDCellTM Aptus Bioreactors, LLC, Clemson, SC, USA)
in batches of five roots per system. The pulmonary trunk was
cannulated with Luer-barbed adaptors and connected to the
perfusion system. The mounting rings are unique in the fact that
they provide a no-touch mounting system for valve roots, which
does not affect cusp or artery integrity. The decellularization
system was perfused by a peristaltic pump with a 30-s off/3-min
on cycle over 12 days under a pressure gradient of 4 mmHg
(between the intraluminal and the external environment), the last
step ending in sterile conditions. Studies performed previously
pointed to improved cell removal from the valve roots when
using perfusion methods in comparison to only immersion
of the heart valves (14, 15). The decellularization procedure
started with 24 h of 0.02% NaN3 in H2O (Sigma-Aldrich
Chemistry, St. Louis, MO, USA) followed by 1 h perfusion of
0.05M NaOH (Lach-Ner, Neratovice, Czech Republic) and rising
with H2O. Three batches of freshly prepared decellularization
solution containing 0.05% sodium dodecyl sulfate (Sigma-
Aldrich Chemistry, St. Louis, MO, USA), 0.5% TRITON X-100
(PanReac AppliChem, Castellar del Vallès, Spain), 0.5% sodium
deoxycholate (Sigma-Aldrich Chemistry, St. Louis, MO, USA),
0.2% ethylenediaminetetraacetic acid (PanReac AppliChem,
Spain) in 10mM hydroxymethyl aminomethane TRIS (Sigma-
Aldrich Chemistry, St. Louis, MO, USA) were circulated for
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48 h each, followed by enzymatic treatments with 720 mU/ml
deoxyribonuclease (PanReac AppliChem, Spain) and 720 mU/ml
ribonuclease (PanReac AppliChem, Spain) for 48 h, at 37◦C,
applied twice. In the last day of the protocol, valves were treated
with 70% ethanol and then 2 h with 0.2% peracetic acid for
sterilization (Merck KgaA, Darmstadt, Germany) and storage in
sterile phosphate-buffered saline (PBS) at 4◦C. Further details can
be found in our previous publication (14, 15).
To validate the extent of cell removal, the scaffolds underwent
quality tests as follows. Histology with 4′,6-diamidino-2-
fenilindol (DAPI) nuclear staining on cryosections (Thermo
Fisher, Waltham, MA, USA) and hematoxylin/eosin assessed
the extracellular matrix architecture and integrity and the
absence of cells nuclei. DNA was also extracted from n = 6
tissue samples from each decellularization batch, quantified by
NanoDrop spectrophotometry and analyzed by EthBr agarose gel
electrophoresis, as described before (15). All valves underwent
sterility testing as follows: decellularized valve fragments were
collected in aseptic conditions, immersed in approximately 3ml
sterile saline, in sterile 15-ml tubes, and transported to the
Microbiology Department of UMFST for further processing.
Culture-based methods were used for testing the sterility of the
valve fragments. For this, each sample was thoroughly vortexed
in 0.5ml sterile saline, and 10 µl was dispersed on blood
agar plates (Oxoid, Hampshire, UK) to isolate the potential
colonizers. Afterwards, each fragment was immersed in 4ml
Muller–Hinton broth (Oxoid, Hampshire, UK) for enrichment
of potentially viable bacteria. The inoculated culture media
were incubated at 37◦C for 18–24 h in normal atmosphere. The
development of colonies and cloudy appearance of the broth
followed, respectively, which indicated bacterial colonization.
For each batch of valve fragments, the saline solution used
for transportation was also tested for potential bacterial
contamination, after mixing in 1:1 proportion with 2 × Muller–
Hinton broth and incubation at 37◦C. A negative control
consisting of Muller–Hinton broth only was also used. The
eventual colonies that grew on blood agar were isolated. If
the broth presented cloudiness, 1 µl was dispersed on blood
agar, to isolate the enriched bacteria. The genus or species of
the isolated bacteria was identified using routine bacteriological
methods (microscopy and biochemical tests). Antibiograms were
performed according to EUCAST standards, for epidemiological
and infection control purposes.
Cells
Adipose-Derived Stem Cells
Subdermal ovine adipose tissue of about 2 cm3 was harvested
from each sheep from the paravertebral region in an aseptic
environment and sterile conditions, in the experimental station
of the university. The tissue was quickly immersed in sterile cell
culture media composed of Dulbecco’s modified Eagle’s medium
(DMEM) (Sigma-Aldrich Chemistry, St. Louis, MO, USA), 10%
fetal bovine serum (Biowest, Nuaille, France), and 1% antibiotic
and antimycotic (Sigma-Aldrich Chemistry, St. Louis, USA) at
37◦C. Using chemical, enzymatic, and mechanical agents, stem
cells were isolated using a method previously described (16).
Adipose-derived stem cells (ADSCs) were cultivated in flasks
with culture media, in an incubator (37◦C, 5% CO2), and
propagated up to passage 3. To extend their usage and availability,
the cells underwent cryopreservation in 10% dimethyl sulfoxide
in 70% DMEM/20% FBS media cryotubes, at a ratio of 2 × 106
cells/vial, first frozen at 2–3◦C/h down to −80◦C in a Corning
CoolCellTM device, followed by storage at−140◦C in a dedicated
freezer. Thawing tests followed by cell culture revealed over 85%
viability of ADSCs after cryopreservation (17). After thawing, the
stem cells were divided into two equal batches and differentiated
toward ECs and separately toward FBs before seeding.
Differentiation Toward Endothelial Cell Lineage
To recreate the endothelium, the ADSCs obtained from each
animal underwent a chemical and mechanical protocol with
minor modifications (18). The ADSCs were cultured on
gelatin-coated culture flasks and fed with differentiation media
composed of Media 199 (Sigma-Aldrich, St. Louis, MO, USA),
13% fetal bovine serum, 12 ml/L antibiotics, 0.1 g/L L-glutamine
(Fisher Scientific, Waltham, MA, USA), and 7.5 U/ml heparin
(Sigma-Aldrich, St. Louis, MO, USA) for 1 week at 37◦C, 5%
CO2. At the beginning of the second week, the media were
supplemented with Endothelial Cell Growth Supplement (ECGS,
from EMD Millipore, Burlington, NA, USA), at a concentration
of 50µg/ml and cells fed for an additional 3 weeks, with passaging
of the cells at a ratio of 1:3, when 80% confluence was reached.
The last week of the differentiation protocol consisted in applying
shear forces to the cells by positioning the plates on an orbital
shaker at 200 rpm (approximately 12 dynes) in a 37◦C, 5% CO2
incubator (19). Cell culture media were replaced every 3–4 days
throughout the experiment. The evaluation of differentiation
was assessed by immunofluorescent microscopy for specific
EC markers: CD 31 (rabbit polyclonal, Abcam, Cambridge,
UK), eNOS (rat polyclonal, Abcam, Cambridge, UK), and
von Willebrand factor (rabbit polyclonal, Abcam, Cambridge,
UK) at dilutions recommend by the antibody supplier. After
differentiation, ECs were frozen in dimethyl sulfoxide (DMSO)
and stored at−140◦C until ready to seed.
Differentiation Toward Fibroblast Cell Lineage
ADSCs differentiation toward FBs was achieved by
supplementing the culture media with 2 ng/ml transforming
growth factor-beta1 (Sigma-Aldrich, St. Louis, MO, USA) (20).
The protocol took place for 3 weeks with media exchange
every 3–4 days and passaging of cells at a confluence of
80%. The assessment of differentiation was performed by
immunofluorescent microscopy and Western blotting for
specific fibroblast cell epitopes: vimentin, Pro-4-hydroxylase,
and collagen type I at dilutions recommend by the antibody
supplier. After differentiation, FBs were frozen in DMSO in
medium and stored at−140◦C until ready to seed.
Seeding
FBs Seeding
To reconstitute the main layers of the valve root, FBs were
seeded internally at the cusps base and externally in the adventitia
layer (Figure 4). First, using a 1-ml syringe, 4 × 106 cells were
suspended in 1ml of culture media, and by injection, the quantity
was equally distributed and introduced at the bases of the three
cusps. After a period of static immersion in culture media for
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4 h, the intraluminal content was separated from the external
volume by placing a plastic plug at the distal arterial end of
the valve (Figure 4). Then, the valve root, while still in the
MechAnnulusTM mounting rings, was placed into an acrylic
jar, and 16 × 106 cells were suspended in the culture media
surrounding the adventitia; the jar containing the TEHV was
rotated for 48 h with one rotation per minute (RPM) in a cell
culture incubator to facilitate FB adherence to the adventitia.
ECs Seeding
ECs seeding consisted likewise of a static and a dynamic phase.
First, 4 × 106 cells suspended in 0.9ml of culture media were
placed in the valve cusps “pockets,” distributed equally in 0.3ml
for each cusp, followed by 4 h of static incubation. After plugging
the lumen with a sterile plug, 16 × 106 cells were suspended
intraluminally in the valve root, and the valves were rotated at 1
rpm for 48 h in a cell culture incubator. For both steps of dynamic
seeding, an air pump was attached to the rotator jars via a sterile
inline filter, continuously enriching the culture media with air
from the CO2 incubator.
Bioreactor Conditioning
The in vivo hemodynamic conditions were replicated in the
laboratory using a dedicated heart valve bioreactor (Aptus
Bioreactors, Clemson, SC, USA). The TEHVs were exposed
cyclically to increasing systolic and diastolic pressures and
frequency over a period of 5 days, until reaching the physiological
pulmonary hemodynamic regimen, as follows. After EC seeding,
the plug was removed, and the distal arterial segment was
sutured to the cylindrical support, stabilizing the pulmonary
artery component of the valve and maintaining it in the
anatomical position. The sterile bioreactor components were
assembled in the sterile hood, containing the seeded valve.
After introducing the culture medium, the bioreactor was placed
in the cell culture incubator (37◦C, 5% CO2), attaching the
air pump to the system as described above with the rotator.
The Aptus PhysioTM software was initiated, and the starting
systolic pressure was set to 10 mmHg at 17 beats per minute
(BPM). On the second day, the pressure was elevated to 15
mmHg at 30 BPM followed by a pressure of 19 mmHg with
45 BPM on the third day. On the last day of conditioning, the
pressure was 24 mmHg at a rate of 60 BPM and maintained
overnight until surgical implantation. Two additional TEHV
were prepared, following identical decellularization, seeding, and
preconditioning protocols. These served as cell-seeded, non-
implanted controls.
Implantation
The animal study had obtained the approval of the University
Ethics Committee of UMFST “George Emil Palade” under
number 131/21.10.2016. Details of the pre- and postoperative
care of the sheep implanted with TEHV have been described in
detail in a recent publication (21).
Experimental animals for this study were sheep, from a
local breed “Tsigai metis” produced at the Reghin Research and
Development Station for Sheep and Goats, Romania.
The female sheep aged between 14 and 18 months were
brought to the Experimental Station of the UMFST, and after 3
weeks of quarantine, while they were examined clinically, they
were treated with ivermectin and randomly divided into two
groups: Group 1, implanted with unseeded, cell-free acellular
pulmonary valve scaffolds (n = 6), and Group 2, implanted with
autologous cells-seeded pulmonary valve scaffolds (n = 6). The
sheep in Group 2 were first used to obtain adipose tissue, as
described above, and while the cells were isolated, differentiated,
and seeded onto scaffolds, the animals were allowed to recover for
about 3 weeks. Just before surgery, the sheep were approximately
17–19 months old and weighed around 53 ± 11 kg. Under
general, inhalation anesthesia, in extracorporeal circulation, the
right ventricle ejection tract was exposed through a lateral
thoracotomy in the left third intercostal space. The TEHV
was removed from its holder, trimmed to size, and prepared
for implantation. After removal of the native pulmonary
valve, the TEHV was implanted in an orthotopic pulmonary
position. Its functionality was evaluated with transesophageal
and epicardial ultrasound at the time of implantation and
at explantation using a Mindray DC-N6 echocardiograph
(Mindray, Shenzhen, China). For the transthoracic approach,
the P7-3 transducer was utilized, respectively, P7-3T, for the
transesophageal ultrasound examination. By two-dimensional
examination, the morphology and movement of the valve
components were examined, in addition to the opening and
closing mechanisms. By Doppler, the competence was evaluated
along with the presence of stenosis. After surgical implantation,
the animals were followed up over a period of 6 months. Clinical
signs were observed and recorded along with their somatic
development. Periodic transthoracic ultrasound examinations
were performed under mild animal intravenous sedation. At
the end of the follow-up period, the sheep weighing about 70
± 9 kg underwent transesophageal and epicardial ultrasound
under general anesthesia with orotracheal intubation followed
by explantation of the valves. Explants were macroscopically
examined and immersed in 10% neutral buffered formaldehyde
(Sigma-Aldrich, St. Louis, MO, USA) followed by embedding
in paraffin. Standard histological sections were performed, and
subsequently, mounting on glass slides and hematoxylin/eosin
staining were realized. For immunohistochemistry, we utilized
a Dako mouse antismooth muscle actin antibody clone 1A4
(M0851) at 1:100 dilution and a horseradish peroxidase (HRP)
detection kit as recommended by the manufacturer (Dako,
Glostrup, Hovedstaden, Denmark). For quantitative analysis,
nine random images were taken at 40× magnification from
a-SMA IHC-stained slides from each group (three from
the valve base, three from the mid leaflet area, and three
from the tip), and the number of positive (brown) cells
per high power field (HPF) was calculated and compared
between groups.
Statistics
Single-factor analysis of variance (ANOVA) was used to compare
infiltrating cell numbers and echocardiographic measurements
between the two TEHV groups.
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RESULTS
Scaffold Decellularization and Sterilization
For this study, we performed nine perfusion decellularization
procedures, yielding a total of 45 decellularized valves. One
valve from each batch of five was randomly selected for quality
control. Macroscopic evaluation of each valve at the end of the
decellularization protocol did not reveal any signs of mechanical
tears in any of the valve components. Decellularized valves
acquired the “snow-white” color typical of acellular tissues.
The sterility tests performed at the protocol finale revealed
the absence of microbial contamination of all valves and of
the storage media, except for four valves, which were removed
from the study. Histological assessment by fluorescent staining
for nuclei (DAPI) and classic optical microscopy (H&E stain)
revealed preserved tissue matrix architecture and the three layers
in the valve cusps, sinuses, and arterial walls along with complete
absence of cell nuclei (Figure 2). These histological findings
were confirmed by DNA extraction and quantitation, showing
>98% reduction of DNA content and total absence of nucleic
material detected by ethidium bromide agarose electrophoresis
(Figure 2).
Scaffold Revitalization With Cells
Fourteen ADSCs cultures were obtained from n = 14 sheep,
generating a total of over 100 × 106 cells. Each batch of cells
was carefully labeled with the sheep number before freezing,
to allow for autologous use later. To extend their availability
and usability, all cells underwent cryopreservation in DMSO
followed by thawing when needed for differentiation. ADSCs
multipotency was confirmed earlier using specific histological
stains after differentiating them toward osteogenic, adipogenic,
and chondrogenic lineages using special kits (17).
ECs Differentiation
Twelve batches of ADSCs were differentiated into ECs in this
study, using cell culture on gelatin-coated flasks in the presence
of ECGS and shear. ADSCs exposed to these conditions displayed
the ability to uptake DiI-AcLDL and were positive for CD31,
vWF, and eNOS markers (Figure 3), while undifferentiated
ADSCs exhibited very little reactivity for these markers and
essentially did not uptake any DiI-LDL. Overall, about 68%
of human ADSCs (hADSCs) stained positive for EC markers
after differentiation.
FBs Differentiation
Twelve batches of FBs were prepared during this study,
generating over 300 × 106 cells. To evaluate the effectiveness
of differentiation, we stained the cells for vimentin, prolyl-
4-hydroxylase (P4H), and collagen type I and analyzed them
by immunofluorescence (Figure 3). In addition, cells were
extracted for protein and analyzed for the presence of the same
markers by Western blotting. ADSCs differentiated into FBs
expressed slightly upregulated levels of vimentin and significantly
upregulated expression of P4H and type I collagen, while
undifferentiated ADSCs expressed very low or undetectable levels
of these FBs markers. Overall, about 75% of hADSCs stained
positive for HSP47, P4H, and COL I.
Cell Seeding and Bioreactor Conditioning
The goal of seeding was to place cells in the appropriate
anatomical areas and revitalize the scaffold before implantation
(Figure 4). To achieve this goal, we first injected FBs in the
valve cusp interstitium, then used solid plugs to separate the
lumen from the adventitia, and rotated the valve in an FBs
suspension for adventitial seeding. Finally, we seeded the valve
lumen with a suspension of ECs on a rotator. The valves
functioned well in the bioreactor, with wide opening (mean
geometrical orifice area of ∼1.4 cm2 for valves of mean
external diameters of approximately 16mm) and perfect closure
(Figure 4). The control TEHVs, i.e., the seeded, conditioned
but not implanted valves, were assessed by histology, which
revealed the presence of FBs at the cusps base and the adventitia
and ECs on the luminal surface of the valve cusps (Figure 4).
Finally, seeded valves were exposed to a gradual increase in the
frequency and pressure until reaching the hemodynamic regimes
of pulmonary circulation. Central closure with complete opening
of the three cusps was observed along with fluid movement
of the sinuses and arterial walls of the valve, synchronically
with the cardiac cycle’s phases—systole and diastole. No signs
of tears or laceration of tissue were documented during the
conditioning protocol.
Surgical Implantation and Follow-Up of
TEHV
All animals included (n= 12) in the study successfully underwent
the surgical implantation procedure. Animals were randomly
divided into Group 1 (n = 6) implanted with acellular scaffolds,
not seeded with cells, and Group 2 (n = 6) acellular scaffolds
seeded with autologous FBs and ECs derived from ADSCs and
conditioned in bioreactors (Figure 5). The first two valves from
Group 1 were explanted early due to infective endocarditis. These
were replaced by two new animals for Group 1. All surgeries
were successful, with an average of 3.5 h of surgery time and with
an average of 70min of cardiopulmonary bypass, without any
associated intraoperative death. In the immediate postoperative
period, animals presented proper clinical status and evolution.
Limited secretions were presented on the pericardial drain before
removal of the tubing. Surgical incisions healed without any signs
of infections or pathological accumulations. No fever or signs
of acute heart failure were recorded. Restoration of vital organ
function was present immediately after extubating.
Functionality evaluation of the TEHVs was periodically
assessed using ultrasound for up to 6 months (Table 1).
The initial evaluation was performed intraoperative using
the transesophageal probe and epicardial access. The two-
dimensional morphological assessment presented physiological
movement of the three cusps with central cooptation and
good opening.
Echocardiography in Group 1, control TEHVs, pointed to
the presence of mediastinal collections in two out of the six
animals and a pericardial effusion that was drained. Animals
presented with preserved ventricular ejection fraction along with
no changes in the cardiac cavities dimension excepting one
animal with light dilatation of the right cardiac cavities resulting
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FIGURE 2 | Pulmonary valve decellularization. Valves were mounted onto purpose-designed external supports and inserted into the pressurized system (A), which
perfused each valve individually (B) with detergents and enzymes. For decellularization validation, DNA was extracted from the sinus and cusp tissues and quantified
by NanoDrop (C), using fresh tissues as controls. Extracted DNA was also run on ethidium bromide agarose gels by electrophoresis and imaged in UV light (D). St,
molecular weight DNA standard ladder; C, fresh cusp; S, fresh sinus; Cd, decellularized cusp, two lanes; Sd, decellularized sinus, two lanes. Histology using H&E
stain of fresh cusp (E), decellularized cusp (F), fresh sinus (G), and decellularized sinus (H) and using DAPI stain for nuclei (blue) in fresh cusp (I), decellularized cusp
(J), fresh sinus (K), and decellularized sinus (L). Bars in all histology images are 200 µm.
from an important valvular regurgitation. Moderate insufficiency
was observed in one animal and trivial in another.
In Group 2 of cell-seeded TEHVs, five out of six animals
developed non-hemodynamically significant circumferential
pericardial collections, with no indication for surgical drainage.
On consecutive exams in two animals, resorption of the liquid
was noted. At repeated exams, two animals presented enlarged
right cavities. One of these two animals additionally developed
valve stenosis with a planimetric measured area of 1.2 cm2. In
terms of regurgitation, one valve presented a moderate degree of
insufficiency but with no impact on the right heart cavities. Due
to technically surgical malposition (higher suture on the TEHV
basis) of one TEHV, it presented mild central regurgitation.
TEHV cusps revealed to be thin, supple, and mobile, with
complete opening on echocardiography. Prior to the animal’s
euthanasia, TEHVs were examined by epicardial ultrasound.
TEHV Explants and Their Analysis
At 6 months after implantation, animals were prepared for
euthanasia and explantation of the TEHV. At explantation, the
implants and anastomoses were intact, and the valve root was
well integrated into the host tissues, with a shiny endothelium
covering the whole implant and the anastomoses, with no
evidence of thrombi. The tubular implants looked unaltered and
could hold saline if added distally, pointing to competent valves.
The implants were then sectioned longitudinally, and opened
roots were photographed. The valve leaflets were unchanged
in size or thickness and were non-fibrotic, thin, supple, and
semitransparent. Numerous cells positive for a-smooth muscle
cell actin were found mostly in the sinus, base, and the fibrosa
of the leaflets, indicating a strong potential for repopulation of
the scaffold. Flat monolayers of endothelial cells were found
on the surfaces of the valve leaflets, the sinus walls, and the
pulmonary artery (Figure 6). No major differences were noted
in performance or cell repopulation of cell-seeded vs. non-cell-
seeded valves in the sheep study.
DISCUSSIONS
Key Findings
In this project, we proposed a translational scenario (Figure 1)
based on our previous experience with acellular valve scaffolds,
which performed very well hemodynamically in the right
ventricular outflow tract (RVOT) in sheep (22, 23). The
decellularization protocol proved to be effective in removing all
nucleic materials while preserving the integrity and architecture
of the ECM, as reported earlier in pilot studies (15). Acellular
valve scaffolds have several advantages: they preserve the
natural 3D architecture, have excellent hemodynamics and
biomechanics, are highly biocompatible, are not antigenic,
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FIGURE 3 | Differentiation of adipose-derived stem cells. (A) For differentiation into ECs, ADSCs were subjected to ECGS media followed by dynamic shear. HUVECs
(ECs) served as controls. For validation, cells were incubated with DiI-labeled LDL (DiI-LDL) and imaged by fluorescence microscopy (intracellular red particles). Cells
were also immunostained for CD31, VWF, and eNOS (green, positive). Nuclei were stained with DAPI. Bars are 100 µm. (B) amounts of positive eNOS, CD31, and
VWF proteins in immunofluorescent images were assessed by semiquantitative image analysis normalized to area. For differentiation into FBs, ADSCs were exposed
to low doses of TGF and stained for (C) vimentin, prolyl-4-hydroxylase (P-4-H), and collagen type I (Coll 1). Cells were also analyzed by Western blotting for same
antigens and band intensity measured in the BioRad imager (D). A semiquantitative analysis of cell differentiation is shown in (E). Asterisk in Panels (B,D) designate
statistically significant differences when compared to UN-DIFF. In all panels, UN-DIFF, undifferentiated stem cells; DIFF, stem cells that have been exposed to EC or FB
differentiation conditions.
maintain integrity for extended periods of time, and serve as
excellent porous substrates for cell adhesion and repopulation
(24, 25). Despite exposing bare collagen surfaces to flowing blood,
we could not detect any thrombus structures in any of the
explants, and there was no need for systemic anticoagulation.
Notably, TEHVs can be considered tissue-derived bioprostheses
heart valves, which, according to current clinical guidelines,
require oral anticoagulation with Vitamin K antagonists for 3
months postoperation (9). In pilot studies, we explanted two
acellular valves: one was explanted early (after 48 h) and a second
after 7 days, both due to non-valve-related issues. As seen by
histology, the valve at 48 h showed a thin layer of fibrin on
the surfaces, which disappeared after 7 days (data not shown)
and clearly was not present on any of the explanted valves at 6
months. This was not investigated systematically in the current
study but confirms results published earlier by us and others
(8, 26). Similarly to other investigators using decellularized valves
(12, 27), in our hands, there was no inflammatory or immune
reaction to the implant, no calcification was noted, and no
pannus or tissue overgrowth was found in any of the valves
analyzed in this study, indicating high biocompatibility and lack
of antigenicity.
Earlier, we seeded acellular valve scaffolds with freshly isolated
autologous stem cells (ADSCs) and immediately implanted them
in sheep, without any stem cell differentiation or any dynamic
bioreactor preconditioning; as most of the cells died within 3–
4 days after implantation, we noted that stem cells were very
vulnerable to dynamic functional pressures and flow (22), which
was also confirmed in vitro using cell-seeded scaffolds tested
in bioreactors (28). To overcome these issues, we hypothesized
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FIGURE 4 | Scaffold seeding and bioreactor preconditioning. (A) Schematic depicting the targeted cell distribution by seeding FBs internally (Int.FBs, blue) as well as
adventitially (Adv.FBs, gray) and ECs in the root lumen, on cusps, sinus, and artery surfaces (ECs, red). (B) FBs seeding by injection in the base of each cusp. (C)
Placing of an aortic plug to separate the lumen from the exterior environment. (D) TEHVs with aortic plugs placed in FBs suspension in the acrylic seeding cups on the
rotator for adventitial seeding. (E) After removal of the plug, the pulmonary artery was temporarily maintained open using three or more single sutures, (E) for
intraluminal seeding of ECs (F). (G) Positioning the seeded valve in the bioreactor, (H) fully assembled heart valve bioreactor just before insertion in the incubator. (I) still
shots saved from video recordings taken during valve conditioning in the bioreactor showing open (top) and closed (bottom) positions. (J) H&E staining of control TEHV
(seeded and preconditioned, not implanted); arrows point to ECs surface coverage, while the cell-rich island in the middle is representative of interstitially injected FBs.
that seeding with mature cells and implementing progressive
dynamic conditioning would enhance the viability of cells after
implantation. Therefore, in current study, we decided to isolate
the stem cells, differentiate them in vitro into more robust FBs
and ECs, and use those cells for scaffold seeding; in addition,
we subjected seeded scaffolds to progressive adaptation in heart
valve bioreactors, by slowly increasing flow, frequency, and
pressures so that within 5 days, the constructs reached pulmonary
valve conditions. Endothelialization is a fundamental target for
researchers and clinicians involved in vascular and valvular
replacements (29, 30). Varied modalities to differentiate and
to promote ADSCs commitment toward ECs were described,
including genomic manipulation (31), immune modulation (32),
induced hypoxia (33), and specific growth factors (34, 35).
Comparative studies of differentiation of ADSCs toward ECs
lineage revealed improved results when combinations of ECGS
and shear were used (36, 37) pointing to the importance of
recreating the in vivo conditions. Finally, in previous works,
we mounted valve scaffolds in acellular pericardial tubes and
implanted them as a shunt in the RVOT, which did not fully
mimic the appropriate clinical application of such valves (22,
23). In the current study, we implanted the revitalized valves
orthotopically using open-heart surgery under cardiopulmonary
bypass (CPB), which better approximates the clinical use of such
valve implants. Cell-seeded valves maintained their viability after
progressive bioreactor conditioning and functioned well in vivo
for 6 months. Cells positive for a-smooth muscle cell actin were
found in the valves interstitium flat monolayers of endothelial
cells were found on the surfaces indicating a strong potential for
repopulation of the scaffolds.
Conclusions
To our knowledge, this is the first study to document preclinical
validation of decellularized valvular scaffolds repopulated
with heart-valve-specific cells differentiated from autologous
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FIGURE 5 | Surgical implantation and follow-up. (A) Removal of the native pulmonary valve; (B) preparation of the TEHV before implantation; (C) final surgical aspect,
postimplantation; (D) insertion of the transesophageal ultrasound probe; (E) intraoperative epicardial ultrasound; (F) postoperative experimental animal transthoracic
ultrasound; (G) transesophageal ultrasound evaluation of the TEHV; (H) postoperative transthoracic evaluation of the cardiac cavities and TEHV.
stem cells and preconditioned before implantation using a
dedicated bioreactor.
Our decellularization protocol resulted in acellular and sterile
heart valve scaffolds, confirmed by histological assessment,
DNA quantitation, and sterility tests. Preserved valve geometry
and structure were documented along with conserved matrix
architecture. Scaffold functionality was further assessed by
ultrasound evaluation while functioning in a bioreactor, revealing
absence of valvular regurgitation (data not shown here). Ovine
ADSCs proved to be a convenient source of stem cells,
their cryopreservation after propagation proving to be a good
option for increasing their availability. Their differentiation
toward heart-valve-specific cell lineages was successful, with
upregulation of major markers, albeit not reaching expressions
of adult mature target cells. Seeding efficacy was not wide
ranging, with areas of scaffolds remaining cell free interstitially;
however, cell viability was maintained during the seeding
protocol. Bioreactor preconditioning did not change the integrity
of the scaffold or the seeded cells. Surgical implantation in
pulmonary position was successful, with no major incidents or
complications, while the animal’s follow-up proved challenging
due to poor transthoracic ultrasound windows and their rapid
somatic growth. Notably, host cells were found populating the
implanted scaffolds in large numbers, with preference for the
cusp base, fibrosa, and spongiosa layers of the valve cusps.
Cells were distributed homogeneously, resembling regeneration
processes more that hyperplasia. Overall, we concluded that cell
seeding did not negatively affect TEHV performance, as they




Minimizing mismatch in the size of implanted valves is very
important clinically (38). Initially, we worked with adult porcine
valves (22), but they were too large for orthotopic implantation
in the ovine pulmonary position; we tested a few valves from
juvenile pigs that matched in size, but it was very difficult for us to
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FIGURE 6 | Explant analysis. (A) Representative macroscopic images of freshly explanted TEHV and (B) cell-seeded TEHV. (C) Representative H&E stain of cells
found within the valve interstitium; (D) immunohistochemistry for alpha-smooth muscle actin (brown, positive). Bar is 200 µm. (E) Quantitative data on alpha-smooth
muscle actin positive cells infiltrated in the base, middle, and tip areas of the TEHVs. Statistical analysis revealed no significant differences in the number of infiltrated
cells between the two valve groups.
ensure a constant supply of juvenile pigs for this study. Thus, we
decided to pursue ovine tissue sources, which were a much better
size match.
Decellularization
Removing all the cells was easily achieved using the perfusion
system utilized before for aortic valve roots, with minor
modifications in procedures (14), including adaptation of the
mounting rings and a diminution of working pressures to less
than physiological 20 mmHg. Sterility and long-term storage are
amajor challenge in TEHV. It is paramount that decellularization
protocols efficiently remove all cells from cusps, muscle, and
artery. In earlier phases of the project, we utilized peracetic acid
sterilization of the valves while they were still mounted in the
support rings, inside the perfusion system. We realized later that
certain areas of the root tissues (clamped in the support rings)
were not sterile because of lack of access to the sterilant. A few of
these valves that were implanted had to be explanted early due to
endocarditis. To solve this issue, we decided to take out the valves
from the rings after decellularization, sterilize the entire root by
immersion, and then remount them in a new set of sterile rings
for further seeding and conditioning. Routine sterility testing of
tissues and storage solutions is highly recommended throughout
the process of manufacturing TEHV.
Cells
ADSCs are relatively easy to isolate and culture from subdermal
adipose tissue samples. In a pilot study, we collected adipose
tissue from several anatomical areas to determine the optimal
source for ADSCs and found the interscapular area as most
favorable (39). When needed, ADSCs can be safely cryopreserved
for later use. Differentiated stem cells expressed some, but not all,
specific markers for FBs or ECs; it is not clear whether this affects
cell behavior after implantation. Furthermore, it is not clear if
cryopreservation could be applied after ADSC differentiation
into FBs and ECs. More detailed studies on ADSC-derived FBs
and ECs are warranted.
Seeding
Manual injection in the cusp interstitium was limited to just a
few sites, and it is not clear if cell migration took place later from
the cell bolus. We do not know at this point if the cells found
in the 6-month explants were the same cells that were seeded
initially, or they were host-derived infiltrated cells. More studies
with cell tracers on a discrete timeline are needed to answer this
question. In addition, improved interstitial seeding methods are
needed to address the need to distribute cells in specific anatomic
areas more homogeneously.
Bioreactor
The ramping-up profile was not optimized but rather designed
rationally. A time-dependent study looking at effects of different
adaptation regimes on cell attachment and viability is needed.We
do know that the bioreactor can maintain cell viability for up to
2 weeks (40). Maintaining valves alive in the bioreactor could
be useful especially if implantation cannot occur as scheduled.
Assembly of the bioreactor and mounting of the valve in sterile
conditions are not trivial and require extensive preparation
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TABLE 1 | Echocardiographic evaluation of the TEHVs.
Timeline Initial evaluation—at implantation End of the follow-up evaluation

















Group 1 - control TEHVs
#1 Normal size and
function
Normal function 0.5 Normal size and
function
Trivial regurgitation 0.7
#2 Normal size and
function
Normal function 0.8 Normal size and
function
Moderate regurgitation 0.5
#3 Normal size and
function
Normal function 0.7 Dilatation of right
ventricle
Important regurgitation 0.7
#4 Normal size and
function
Normal function 0.6 Normal size and
function
Normal function 0.6
#5 Normal size and
function
Normal function 0.5 Normal size and
function
Normal function 0.7
#6 Normal size and
function
Normal function 0.8 Normal size and
function
Normal function 0.7
Mean +/– SEM 0.65+/– 0.13 Mean +/– SEM 0.65+/−0.08
Group 2 - cell seeded TEHVs
#1 Normal size and
function
Normal function 0.7 Dilated right ventricle Important regurgitation 0.5
#2 Normal size and
function
Normal function 0.8 Normal size and
function
Normal function 0.7
#3 Normal size and
function
Normal function 0.5 Normal size and
function
Moderate regurgitation 0.6
#4 Normal size and
function
Normal function 0.6 Normal size and
function
Normal function 0.6
#5 Normal size and
function




the TEHV with impaired
opening of the cusps
2.4
#6 Normal size and
function
Mild regurgitation 0.7 Normal size and
function
Mild regurgitation 0.7
Mean +/– SEM 0.66 +/– 0.10 Mean +/– SEM 0.91 +/−0.73
Statistical analysis revealed no significant difference between the mean maximum trans-TEHV velocity between the two groups at all time points (p = 0.06).
and attention to detail. Preassembly of the major bioreactor
components (reservoirs, connecting tubes, transducers, and atrial
and ventricular chambers) in the sterile hood was instrumental
in reducing the time it took for rapid mounting of the living
valves. In our hands, no signs of microbial contamination
of the valves or the culture media were observed during
bioreactor conditioning.
Implantation
Despite timely coordination between the tissue engineering
lab and the operating room, valve preparation in the operating
theater can sometimes take longer than expected, or the
patient could require extra care before implantation. This
raises the question of how to maintain valve viability while
in the operating room, using cold storage, a temporary warm
storage solution, or even a transportation bioreactor. In
the current study, the lab was in the vicinity of the animal
facility, which reduced transportation time to a minimum.
Echocardiography in sheep was found difficult unless in
the open chest, where transepicardial access allowed for
excellent imaging. The heart and its structures were periodically
examined through non-standard transthoracic echocardiography
windows given the brisk animal’s somatic development in the
postoperative period and emerging distortions in the mediastinal
anatomy; these aspects represented significant limitations
for an adequate ultrasound evaluation. Additionally, in the
immediate postoperative period, examinations were limited
by postsurgical inflammation processes. Considering the
above stated constraints, the transthoracic examinations
were restricted to evaluation of mediastinal collections.
Visualization of TEHV proceeded with morphological
evaluation of valve components, interrogation with both
color and pulse Doppler, and evaluation of the existence of
any degree of regurgitation, stenosis, or both. Regarding the
TEHVs, when they could not be visualized directly, appearance
of indirect signs of valvular dysfunction such as dimension
and functionality of the right and left ventricles and atria
was assessed.
Post Explant Analysis
Histology on unimplanted decellularized tissues is sometimes
tricky. The classical stains do not always bind efficiently to
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decellularized tissue components, and elastin autofluoresces
intensely after decellularization. We found that washing
of detergent-decellularized tissues with 70% ethanol before
histological processing improved outcomes of histological
analysis. Histology on explanted tissue, however, worked out
much better, presumably because of host cells and protein
infiltration. Immunohistochemistry was also found difficult at
times because of paucity of antisheep antibodies and, at times,
the diaminobenzidine reagent bound to collagen in decellularized
tissues in the absence of any antibodies.
Future Directions for Research
Further work needs to be performed to fine-tune the different
aspects of this translational scenario. Stem cells could be obtained
from other sources, including induced pluripotent stem cells
(iPSCs), and these could be differentiated in vitro into the desired
target cells. Seeding devices capable of inserting cells in the
appropriate sites are currently being designed and tested in
our group. Seeded cells should be labeled by a permanent tag
that would be stable and transmissible to daughter cells and
monitored via a convenient imaging technique. This type of
study should be implemented together with a more detailed long-
term investigation with more numerous time points, looking
at the fate of TEHV implanted in juvenile sheep and how
they adapt to somatic growth. This should be accompanied
by more reliable imaging follow-up; investigation of blood
parameters of inflammation, immune reactions, and coagulation;
and precise assessment of the ability of the TEHV to grow
with the somatic growth of the patient. To assess growth,
markers should be placed strategically in different areas of the
implant, and tissue thickness should be measured at all time
points. A comparison of cell-seeded scaffolds with cell-free
scaffolds will allow to draw important conclusions relative to
the need for in vitro repopulation before implantation, currently
a topic of controversy. Several groups are investigating cell-
free approaches, relying on the body’s ability to repopulate or
regenerate scaffolds with the appropriate cells (41, 42); however,
it is not clear at the moment whether this response is a true
regenerative process or a fibrotic healing reaction. We also
do not know if implantation of a cell-seeded TEHV would
stimulate or suppress local regenerative and/or fibrotic processes.
Overall, we believe that with our approach, we are getting
closer to the target, and with further interrogation, successful
implementation of TEHV will benefit pediatric patients and
young adults.
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